Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Study Phase : Approved
Recipient : Chia Tai Tianqing Pharmaceutical Group
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.
Brand Name : Emend-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 22, 2023
Lead Product(s) : Fosaprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Recipient : Chia Tai Tianqing Pharmaceutical Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lovenox-Generic (enoxaparin sodium) is a Factor XI/XIa inhibitor with a Prefilled Syringes with 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths low molecular weight heparin (LMWH), is an anticoagulant that helps to prevent thrombosis.
Brand Name : Lovenox-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 08, 2023
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Enoxaparin sodium binds to antithrombin III, a serine protease inhibitor, forming a complex that irreversibly inactivates factor Xa, which is frequently used to monitor anticoagulation in the clinical setting.
Brand Name : Lovenox-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?